BR9909358A - Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito - Google Patents

Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito

Info

Publication number
BR9909358A
BR9909358A BR9909358-8A BR9909358A BR9909358A BR 9909358 A BR9909358 A BR 9909358A BR 9909358 A BR9909358 A BR 9909358A BR 9909358 A BR9909358 A BR 9909358A
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
chronic complications
diabetes mellitus
prevent
Prior art date
Application number
BR9909358-8A
Other languages
English (en)
Inventor
Michael Lee Jones
David Gunn
John Howard Jones
Michael C Van Zandt
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of BR9909358A publication Critical patent/BR9909358A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, PROCESSO PARA PREVENçãO OU ALìVIO DE COMPLICAçõES CRÈNICAS DECORRENTES DE DIABETES MELITO". São descritos ácidos indol-alcanóicos substituídos úteis no tratamento de complicações crónicas decorrentes de diabetes melito. Também são descritas composições farmacêuticas contendo os compostos e processos de tratamento empregnando os compostos, bem como processos para sua síntese.
BR9909358-8A 1998-03-31 1999-03-31 Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito BR9909358A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8014398P 1998-03-31 1998-03-31
PCT/US1999/007116 WO1999050268A2 (en) 1998-03-31 1999-03-31 Substituted indolealkanoic acids

Publications (1)

Publication Number Publication Date
BR9909358A true BR9909358A (pt) 2000-12-12

Family

ID=22155536

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909358-8A BR9909358A (pt) 1998-03-31 1999-03-31 Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito

Country Status (29)

Country Link
US (9) US6214991B1 (pt)
EP (1) EP1066283B1 (pt)
JP (2) JP3494990B2 (pt)
KR (1) KR100584650B1 (pt)
CN (1) CN1205207C (pt)
AP (1) AP2000001929A0 (pt)
AT (1) ATE269861T1 (pt)
AU (1) AU774929B2 (pt)
BG (1) BG65446B1 (pt)
BR (1) BR9909358A (pt)
CA (1) CA2383983C (pt)
CZ (1) CZ300706B6 (pt)
DE (1) DE69918278T2 (pt)
EE (1) EE200000573A (pt)
ES (1) ES2224632T3 (pt)
HU (1) HUP0101672A3 (pt)
ID (1) ID27884A (pt)
IL (2) IL138711A0 (pt)
MX (1) MXPA02003122A (pt)
NO (1) NO20004900L (pt)
NZ (1) NZ507172A (pt)
OA (1) OA11622A (pt)
PL (1) PL201645B1 (pt)
SK (1) SK7522001A3 (pt)
TR (1) TR200002869T2 (pt)
TW (1) TWI243163B (pt)
WO (1) WO1999050268A2 (pt)
YU (1) YU59600A (pt)
ZA (1) ZA200005577B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200002869T2 (tr) * 1998-03-31 2000-12-21 The Institute For Pharmaceutical Discovery,Inc. İkame edilmiş indolealkonik asitler.
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
JP2003505369A (ja) * 1999-07-15 2003-02-12 エヌピーエス アレリックス コーポレーション 偏頭痛を治療するための複素環式化合物
WO2001064205A2 (en) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
US20020012630A1 (en) * 2000-05-09 2002-01-31 James Nolan Methods for testing compounds useful in treating diabetic complications
CA2433100A1 (en) 2000-12-27 2002-07-04 Helmut Haning Indole derivatives as ligands of thyroid receptors
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US6770655B2 (en) 2002-01-18 2004-08-03 Aryx Therapeutics 5-HT3 receptor antagonists and methods of use
CA2395871A1 (en) * 2002-07-26 2004-01-26 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids derivatives and formulations containing same for use in treatment of diabetic complications
BR0312972A (pt) * 2002-07-26 2005-06-14 Inst For Pharm Discovery Inc Derivado de ácidos indolalcanóicos substituìdos e formulações contendo o mesmo para o uso no tratamento de complicações diabéticas
DK1537078T3 (da) * 2002-08-29 2010-08-02 Merck Sharp & Dohme Indoler med anti-diabetisk aktivitet
CN1726190A (zh) 2002-12-10 2006-01-25 惠氏公司 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－羰基－1h－吲哚－1－基乙酸衍生物
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CA2509222A1 (en) 2002-12-10 2004-06-24 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
CN1723197A (zh) 2002-12-10 2006-01-18 惠氏公司 作为纤溶酶原激活物抑制剂－1(pai－1)的抑制剂的取代3－烷基和3－芳基烷基1h－吲哚－1－基乙酸衍生物
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP4828414B2 (ja) * 2003-04-28 2011-11-30 ニツポネツクス・インコーポレーテツド インドール酢酸誘導体および薬剤としてのそれらの使用
JP2006525329A (ja) * 2003-04-30 2006-11-09 ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー 置換カルボン酸類
CA2534649A1 (en) * 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
CA2585555A1 (en) * 2004-10-28 2006-05-11 The Institutes For Pharmaceutical Discovery, Llc Substituted phenylalkanoic acids
ZA200705872B (en) * 2005-01-14 2008-09-25 Genelabs Tecnologies Inc Indole derivatives for treating viral infections
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US20080051384A1 (en) * 2006-07-14 2008-02-28 Genelabs Technologies, Inc. Antiviral agents
RU2458918C2 (ru) 2006-07-22 2012-08-20 Оксаген Лимитед Соединения, обладающие антагонистической активностью по отношению к crth2
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
MX2010007833A (es) 2008-01-18 2010-08-11 Oxagen Ltd Compuestos que tienen actividad antagonista de crth2.
WO2009093029A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
US20100022613A1 (en) * 2008-01-22 2010-01-28 Oxagen Limited Compounds Having CRTH2 Antagonist Activity
GB2457040A (en) * 2008-01-30 2009-08-05 Oxagen Ltd 1-Acetic acid indole derivatives with PGD2 activity
KR101357438B1 (ko) 2009-04-29 2014-02-06 아마린 코포레이션 피엘씨 Ｅｐａ 및 심혈관 제제를 포함하는 제약 조성물 및 그의 사용 방법
RS63796B1 (sr) * 2010-07-16 2022-12-30 Univ Columbia Inhibitori aldoza reduktaze i njihova upotreba
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
RS61239B1 (sr) 2016-06-21 2021-01-29 Univ Columbia Inhibitori aldozne reduktaze i postupci korišćenja
RU2020107188A (ru) 2017-07-28 2021-08-30 Эпплайд Терапьютикс Инк. Композиции и способы лечения галактоземии
US11530186B2 (en) 2018-03-29 2022-12-20 H. Lee Moffitt Cancer Center and Research Center Institute, Inc. Inhibitors for the β-catenin / T-cell factor protein-protein interaction
SG11202111822QA (en) 2019-05-07 2021-11-29 Univ Miami Treatment and detection of inherited neuropathies and associated disorders

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4442118A (en) * 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
DE3684410D1 (de) * 1985-11-07 1992-04-23 Pfizer Heterocyclische oxophthalazinylessigsaeure.
US4960785A (en) * 1988-12-16 1990-10-02 Pfizer Inc. Indolinone derivatives
WO1993012786A1 (en) * 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US5064852A (en) * 1988-12-16 1991-11-12 Pfizer Inc. Indolinone derivatives
AU5279390A (en) 1989-03-31 1990-11-05 Kyoto Pharmaceutical Industries, Ltd. New imidazole derivatives, production thereof, and uses thereof as medicines
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
WO1991009019A1 (en) 1989-12-15 1991-06-27 Pfizer Inc. Substituted oxophthalazinyl acetic acids and analogs thereof
US5312829A (en) * 1990-05-21 1994-05-17 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
GB9011335D0 (en) 1990-05-21 1990-07-11 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5116753A (en) * 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
JPH0641071A (ja) * 1991-09-06 1994-02-15 Taisho Pharmaceut Co Ltd インドール酢酸エステル誘導体
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
GB9409583D0 (en) 1994-05-13 1994-07-06 Pfizer Ltd Indoles
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5700819A (en) * 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
CZ288897A3 (cs) * 1995-03-20 1998-02-18 Eli Lilly And Company V poloze 5-substituovaný 3-(1,2,3,6-tetrahydropyridin-4-yl)indol a 3-(piperidin-4-yl)indol a farmaceutický prostředek, který je obsahuje
JPH09165371A (ja) 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
TR200002869T2 (tr) * 1998-03-31 2000-12-21 The Institute For Pharmaceutical Discovery,Inc. İkame edilmiş indolealkonik asitler.
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
WO2001064205A2 (en) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Also Published As

Publication number Publication date
CZ20003607A3 (cs) 2001-03-14
AP2000001929A0 (en) 2000-09-30
US7105514B2 (en) 2006-09-12
IL138711A0 (en) 2001-10-31
SK7522001A3 (en) 2002-02-05
AU774929B2 (en) 2004-07-15
US6214991B1 (en) 2001-04-10
OA11622A (en) 2004-09-16
US20120270912A1 (en) 2012-10-25
NO20004900L (no) 2000-10-17
KR100584650B1 (ko) 2006-05-30
ES2224632T3 (es) 2005-03-01
US20070093530A1 (en) 2007-04-26
US6426344B2 (en) 2002-07-30
JP2002509931A (ja) 2002-04-02
JP3494990B2 (ja) 2004-02-09
EE200000573A (et) 2002-04-15
BG104819A (en) 2001-05-31
PL201645B1 (pl) 2009-04-30
US6730794B2 (en) 2004-05-04
US8163932B2 (en) 2012-04-24
CN1296485A (zh) 2001-05-23
CA2383983C (en) 2009-09-29
ID27884A (id) 2001-05-03
ZA200005577B (en) 2002-02-11
US20010016661A1 (en) 2001-08-23
EP1066283A2 (en) 2001-01-10
JP2003155274A (ja) 2003-05-27
DE69918278T2 (de) 2005-07-14
WO1999050268A3 (en) 1999-12-16
KR20010042330A (ko) 2001-05-25
IL138711A (en) 2006-09-05
HUP0101672A2 (hu) 2002-04-29
AU3459599A (en) 1999-10-18
CN1205207C (zh) 2005-06-08
NO20004900D0 (no) 2000-09-29
EP1066283B1 (en) 2004-06-23
NZ507172A (en) 2003-10-31
US20100137301A1 (en) 2010-06-03
YU59600A (sh) 2002-12-10
WO1999050268A2 (en) 1999-10-07
DE69918278D1 (de) 2004-07-29
US7659269B2 (en) 2010-02-09
HUP0101672A3 (en) 2002-05-28
US7304079B2 (en) 2007-12-04
BG65446B1 (bg) 2008-08-29
MXPA02003122A (es) 2004-04-21
CZ300706B6 (cs) 2009-07-22
CA2383983A1 (en) 1999-10-07
US20080214540A1 (en) 2008-09-04
TWI243163B (en) 2005-11-11
ATE269861T1 (de) 2004-07-15
PL348244A1 (en) 2002-05-20
US20030018053A1 (en) 2003-01-23
TR200002869T2 (tr) 2000-12-21
US20040235933A1 (en) 2004-11-25
US20100324039A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
DE69530389D1 (de) Dexanabinol-derivate und ihre verwendung als neuroprotektive pharmazeutische zusammensetzungen
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BRPI9915985B8 (pt) 2-cianopirrolidinas n-substituídas, composição farmacêutica que as compreende e uso das mesmas
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
BR0317268A (pt) Compostos ativadores da pirazina e da piridina glucoquinase 5-substituìda, composição farmacêutica, uso e processo de preparação dos mesmos
BRPI0409969A (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
NO940038D0 (no) Arylsulfonamido-substituerte hydrokamsyrer
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
AU2002350191A8 (en) Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
CA2234642A1 (en) 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
BG104899A (en) Antipicornaviral compounds and compositions, their pharmaceutical use and materials for their synthesis
CA2047744A1 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
ATE40681T1 (de) Neue carbonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung sowie arzneimittel, die diese verbindungen enthalten.
AP2001002377A0 (en) Substituted phenoxyacetic acids.
FI945975A (fi) Haarautuneella aminoryhmällä substituoituja tiatsoleja, menetelmiä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
SE9903894D0 (sv) Novel compounds
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
PT1087759E (pt) Processo para a producao de um laminado compreendendo varias camadas individuais
SE9504618D0 (sv) New Compounds

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: A61K 31/404, A61K 31/403, A61K 31/428, A61P 3/00, C07D 209/00, C07D 417/06

Ipc: C07D 417/06 (2008.04), C07D 209/10 (2008.04)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O E 13 DA LEI 9.279/96

B12B Appeal against refusal [chapter 12.2 patent gazette]